These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37783321)

  • 1. Antibodies and α-synuclein: What to target against Parkinson's Disease?
    Otzen DE
    Biochim Biophys Acta Proteins Proteom; 2024 Feb; 1872(2):140943. PubMed ID: 37783321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
    Mehra S; Sahay S; Maji SK
    Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase separation and other forms of α-Synuclein self-assemblies.
    Poudyal M; Sakunthala A; Mukherjee S; Gadhe L; Maji SK
    Essays Biochem; 2022 Dec; 66(7):987-1000. PubMed ID: 36373662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology.
    Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA
    Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
    Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
    J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
    Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
    Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
    Sahay S; Ghosh D; Singh PK; Maji SK
    Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
    Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
    Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermediates of α-synuclein aggregation: Implications in Parkinson's disease pathogenesis.
    Gadhe L; Sakunthala A; Mukherjee S; Gahlot N; Bera R; Sawner AS; Kadu P; Maji SK
    Biophys Chem; 2022 Feb; 281():106736. PubMed ID: 34923391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Molecule Detection of α-Synuclein Oligomers in Parkinson's Disease Patients Using Nanopores.
    Liu Y; Wang X; Campolo G; Teng X; Ying L; Edel JB; Ivanov AP
    ACS Nano; 2023 Nov; 17(22):22999-23009. PubMed ID: 37947369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models.
    Weihofen A; Liu Y; Arndt JW; Huy C; Quan C; Smith BA; Baeriswyl JL; Cavegn N; Senn L; Su L; Marsh G; Auluck PK; Montrasio F; Nitsch RM; Hirst WD; Cedarbaum JM; Pepinsky RB; Grimm J; Weinreb PH
    Neurobiol Dis; 2019 Apr; 124():276-288. PubMed ID: 30381260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
    Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
    J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biasing the native α-synuclein conformational ensemble towards compact states abolishes aggregation and neurotoxicity.
    Carija A; Pinheiro F; Pujols J; Brás IC; Lázaro DF; Santambrogio C; Grandori R; Outeiro TF; Navarro S; Ventura S
    Redox Biol; 2019 Apr; 22():101135. PubMed ID: 30769283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of Noradrenaline to Native and Intermediate States during the Fibrillation of α-Synuclein Leads to the Formation of Stable and Structured Cytotoxic Species.
    Singh P; Bhat R
    ACS Chem Neurosci; 2019 Jun; 10(6):2741-2755. PubMed ID: 30917654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The remarkable conformational plasticity of alpha-synuclein: blessing or curse?
    Deleersnijder A; Gerard M; Debyser Z; Baekelandt V
    Trends Mol Med; 2013 Jun; 19(6):368-77. PubMed ID: 23648364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphic Alpha-Synuclein Oligomers: Characterization and Differential Detection with Novel Corresponding Antibodies.
    Moore K; Sengupta U; Puangmalai N; Bhatt N; Kayed R
    Mol Neurobiol; 2023 May; 60(5):2691-2705. PubMed ID: 36707462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-synuclein aggregation and its modulation.
    Ghosh D; Mehra S; Sahay S; Singh PK; Maji SK
    Int J Biol Macromol; 2017 Jul; 100():37-54. PubMed ID: 27737778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphic α-Synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein.
    Sengupta U; Puangmalai N; Bhatt N; Garcia S; Zhao Y; Kayed R
    Mol Neurobiol; 2020 Jun; 57(6):2741-2765. PubMed ID: 32350746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
    Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles.
    Doucet M; El-Turabi A; Zabel F; Hunn BHM; Bengoa-Vergniory N; Cioroch M; Ramm M; Smith AM; Gomes AC; Cabral de Miranda G; Wade-Martins R; Bachmann MF
    PLoS One; 2017; 12(8):e0181844. PubMed ID: 28797124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.